|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liang H and Kim YH: Identifying molecular
drivers of gastric cancer through next-generation sequencing.
Cancer Lett. 340:241–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan P and Yeoh KG: Genetics and molecular
pathogenesis of gastric adenocarcinoma. Gastroenterology.
149:1153–1162.e1153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berlth F, Bollschweiler E, Drebber U,
Hoelscher AH and Moenig S: Pathohistological classification systems
in gastric cancer: Diagnostic relevance and prognostic value. World
J Gastroenterol. 20:5679–5684. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Katona BW and Rustgi AK: Gastric Cancer
Genomics: Advances and future directions. Cell Mol Gastroenterol
Hepatol. 3:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arkenau HT: Gastric cancer in the era of
molecularly targeted agents: Current drug development strategies. J
Cancer Res Clin Oncol. 135:855–866. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paasinen-Sohns A, Koelzer VH, Frank A,
Schafroth J, Gisler A, Sachs M, Graber A, Rothschild SI, Wicki A,
Cathomas G and Mertz KD: Single-center experience with a targeted
next generation sequencing assay for assessment of relevant somatic
alterations in solid tumors. Neoplasia. 19:196–206. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams HL, Walsh K, Diamond A, Oniscu A
and Deans ZC: Validation of the Oncomine™ focus panel for
next-generation sequencing of clinical tumour samples. Virchows
Arch. 473:489–503. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee A, Lee SH, Jung CK, Park G, Lee KY,
Choi HJ, Min KO, Kim TJ, Lee EJ and Lee YS: Use of the Ion AmpliSeq
cancer hotspot panel in clinical molecular pathology laboratories
for analysis of solid tumours: With emphasis on validation with
relevant single molecular pathology tests and the Oncomine Focus
Assay. Pathol Res Pract. 214:713–719. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sim NL, Kumar P, Hu J, Henikoff S,
Schneider G and Ng PC: SIFT web server: Predicting effects of amino
acid substitutions on proteins. Nucleic Acids Res. 40:W452–W457.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adzhubei I, Jordan DM and Sunyaev SR:
Predicting functional effect of human missense mutations using
PolyPhen-2. Curr Protoc Hum Genet. 7(Unit7.20)2013.PubMed/NCBI
|
|
13
|
Forbes SA, Beare D, Bindal N, Bamford S,
Ward S, Cole CG, Jia M, Kok C, Boutselakis H, De T, et al: COSMIC:
High-resolution cancer genetics using the catalogue of somatic
mutations in cancer. Curr Protoc Hum Genet. 91:10.11.1–10.11.37.
2016. View
Article : Google Scholar
|
|
14
|
Matsusaka S, Kobunai T, Yamamoto N, Chin
K, Ogura M, Tanaka G, Matsuoka K, Ishikawa Y, Mizunuma N and
Yamaguchi T: Prognostic impact of KRAS mutant type and MET
amplification in metastatic and recurrent gastric cancer patients
treated with first-line S-1 plus cisplatin chemotherapy. Genes
Cancer. 7:27–35. 2016.PubMed/NCBI
|
|
15
|
Serra O, Galán M, Ginesta MM, Calvo M,
Sala N and Salazar R: Comparison and applicability of molecular
classifications for gastric cancer. Cancer Treat Rev. 77:29–34.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alessandrini L, Manchi M, De Re V,
Dolcetti R and Canzonieri V: Proposed molecular and miRNA
classification of gastric cancer. Int J Mol Sci. 19:16832018.
View Article : Google Scholar
|
|
17
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi
ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing
and comprehensive molecular profiling identify new driver mutations
in gastric cancer. Nat Genet. 46:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salomao M, Luna AM, Sepulveda JL and
Sepulveda AR: Mutational analysis by next generation sequencing of
gastric type dysplasia occurring in hyperplastic polyps of the
stomach: Mutations in gastric hyperplastic polyps. Exp Mol Pathol.
99:468–473. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ge S, Li B, Li Y, Li Z, Liu Z, Chen Z, Wu
J, Gao J and Shen L: Genomic alterations in advanced gastric cancer
endoscopic biopsy samples using targeted next-generation
sequencing. Am J Cancer Res. 7:1540–1553. 2017.PubMed/NCBI
|
|
21
|
Ichikawa H, Nagahashi M, Shimada Y, Hanyu
T, Ishikawa T, Kameyama H, Kobayashi T, Sakata J, Yabusaki H,
Nakagawa S, et al: Actionable gene-based classification toward
precision medicine in gastric cancer. Genome Med. 9:932017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi J, Yao D, Liu W, Wang N, Lv H, Zhang
G, Ji M, Xu L, He N, Shi B and Hou P: Highly frequent PIK3CA
amplification is associated with poor prognosis in gastric cancer.
BMC Cancer. 12:502012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JW, Lee HS, Nam KH, Ahn S, Kim JW, Ahn
SH, Park DJ, Kim HH and Lee KW: PIK3CA mutations are associated
with increased tumor aggressiveness and Akt activation in gastric
cancer. Oncotarget. 8:90948–90958. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jang SH, Kim KJ, Oh MH, Lee JH, Lee HJ,
Cho HD, Han SW, Son MW and Lee MS: Clinicopathological significance
of elevated PIK3CA expression in gastric cancer. J Gastric Cancer.
16:85–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thumkeo D, Watanabe S and Narumiya S:
Physiological roles of Rho and Rho effectors in mammals. Eur J Cell
Biol. 92:303–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang K, Kan J, Yuen ST, Shi ST, Chu KM,
Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing
identifies frequent mutation of ARID1A in molecular subtypes of
gastric cancer. Nat Genet. 43:1219–1223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng N, Goh LK, Wang H, Das K, Tao J, Tan
IB, Zhang S, Lee M, Wu J, Lim KH, et al: A comprehensive survey of
genomic alterations in gastric cancer reveals systematic patterns
of molecular exclusivity and co-occurrence among distinct
therapeutic targets. Gut. 61:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pai P, Rachagani S, Dhawan P and Batra SK:
Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: An
unholy nexus. Carcinogenesis. 37:223–232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Wu WK, Xing R, Wong SH, Liu Y, Fang
X, Zhang Y, Wang M, Wang J, Li L, et al: Distinct subtypes of
gastric cancer defined by molecular characterization include novel
mutational signatures with prognostic capability. Cancer Res.
76:1724–1732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Horak P, Frohling S and Glimm H:
Integrating next-generation sequencing into clinical oncology:
Strategies, promises and pitfalls. ESMO Open. 1:e0000942016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kuboki Y, Yamashita S, Niwa T, Ushijima T,
Nagatsuma A, Kuwata T, Yoshino T, Doi T, Ochiai A and Ohtsu A:
Comprehensive analyses using next-generation sequencing and
immunohistochemistry enable precise treatment in advanced gastric
cancer. Ann Oncol. 27:127–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tirino G, Pompella L, Petrillo A, Laterza
MM, Pappalardo A, Caterino M, Orditura M, Ciardiello F, Galizia G
and De Vita F: What's new in gastric cancer: The therapeutic
implications of molecular classifications and future perspectives.
Int J Mol Sci. 19:26592018. View Article : Google Scholar
|
|
34
|
Min L, Zhao Y, Zhu S, Qiu X, Cheng R, Xing
J, Shao L, Guo S and Zhang S: Integrated analysis identifies
molecular signatures and specific prognostic factors for different
gastric cancer subtypes. Transl Oncol. 10:99–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Birkenkamp-Demtroder K, Hahn SA, Mansilla
F, Thorsen K, Maghnouj A, Christensen R, Oster B and Orntoft TF:
Keratin23 (KRT23) knockdown decreases proliferation and affects the
DNA damage response of colon cancer cells. PLoS One. 8:e735932013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pellino A, Riello E, Nappo F, Brignola S,
Murgioni S, Djaballah SA, Lonardi S, Zagonel V, Rugge M, Loupakis F
and Fassan M: Targeted therapies in metastatic gastric cancer:
Current knowledge and future perspectives. World J Gastroenterol.
25:5773–5788. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ho SWT and Tan P: Dissection of gastric
cancer heterogeneity for precision oncology. Cancer Sci.
110:3405–3414. 2019. View Article : Google Scholar : PubMed/NCBI
|
